ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Easka, I would be highly surprised if AbbVie is not involved in one way or another. We know that ANIP's R&D cost were too small to account for the follow-up with the 3,656 trial participants. AbbVie is the logical choice , especially with Snabes working simultaneously at AbbVie and Biosante in January 2013, later taking down his Linkedin page when this was discussed, and then activating his Linkedin page while editing it to make it look like he was let go by Biosante then got hired one month later by AbbVie. Additionally, in May or June, 2012, as Biosante is going through a reverse split to stay listed on NASDAQ, Biosante promotes Pat Fuller to VP of IT. She then goes on to contract work for AbbVie in 2013. I strongly believe it was her reward for ensuring a smooth transfer of all the Libigel trial data to AbbVie, so Dr. Snabes could continue following up with the patients. This is most likely how they made the breast cancer reduction discovery.

Though a partnership with Merck and Organon would be a very good alternative, with Organon focusing on HSDD and Merck focusing Cardiovascular and Breast cancer related indications.

I know Art had said they were exploring how to best use the safety data, it would be very interesting if ANIP was able to work out a deal bring all three companies to the table.

In any event the lid on this story should start lifting in the next two weeks. I don't know how long it will take to post the results, once submitted. If consistent with earlier findings, it will get lots of attention from investors and the medical science community.

GLTA